Healthcare
Commented by Juliane Zielonka on September 23rd, 2022 | 11:28 CEST
Defence Therapeutics, Amazon, BioNTech - Innovative technologies for health
While WHO Director-General Tedros Adhanom Ghebreyesus sees the end of the Corona pandemic within reach, companies like BioNTech have more products in the pipeline to bring successful drugs to market. In order to ensure that this happens thoroughly and more quickly, Canadian company Defence Therapeutics is stepping up to shorten development cycles with a unique platform technology in oncology. Cancer has still not been eradicated. An end, however, is in sight for Amazon's in-house healthcare division. Amazon Care is closing its doors at the end of the year, but the Seattle-based corporation still cannot let go of the lucrative healthcare business...
Read
Commented by Stefan Feulner on April 29th, 2022 | 11:16 CEST
BioNTech, NervGen, Sanofi - The rebound is on the way
Uncertainties remain. Admittedly, infection figures are falling in the Corona pandemic and should ensure a quiet summer in this respect. In addition to inflation remaining at a high level, the Ukraine conflict moved to the front news pages. It has caused panic and strong sales on the stock markets in recent weeks. After the DAX marked another interim low at around 13,500 points yesterday, the stock market barometer turned around but is struggling with the psychologically important mark at 14,000 points. Now the quarterly season has begun, which could provide positive impetus. Commerzbank and Deutsche Bank started it off and were quite convincing.
Read
Commented by Nico Popp on October 15th, 2021 | 10:10 CEST
MorphoSys, Sativa Wellness Group, CureVac: Healthcare investments of tomorrow
The healthcare sector is facing a reassessment. For years, especially in Germany, health care has been "fiddled with" - a reform here, a change there, but in basic terms, little has changed in the system in recent years. With the new federal government, things could start to move. Regardless of ideological trench warfare, observers can state, especially under the impression of the pandemic, that innovative treatment methods and preventive care are the most important trends for the future, along with the digitization of the healthcare system. In this context, we present three companies and highlight their opportunities.
Read
Commented by Nico Popp on March 17th, 2021 | 07:25 CET
Fresenius SE, Q+M Dental Group, Siemens Healthineers: Where growth meets dividends
The back-and-forth surrounding AstraZeneca's vaccine has unsettled many people. But the discussion about extremely rare side effects also shows: Vaccines and drugs are subject to strict regulations and the healthcare system is strictly regulated. While pharmaceutical companies must always expect setbacks, especially in accelerated approval procedures, the situation is different for suppliers of medical technology or consumables. We present three stocks that are benefiting from rising healthcare spending.
Read
Commented by Nico Popp on January 19th, 2021 | 10:50 CET
Pfizer, Q&M Dental Group, Johnson & Johnson: Where do profiteers of the pandemic lurk?
We all know that one's health is the most important thing. But from time to time, this truism slips out of focus. The pandemic has shown that neither fame nor money can protect you from getting sick. A big step toward being healthy, however, can be made by trusting in research. The development of vaccines in record time has shown how great the potential is in science and the pharmaceutical industry. New test methods are continually coming onto the market. Three shares show that there is money to be made on the stock market from these developments.
Read
Commented by Carsten Mainitz on January 12th, 2021 | 10:28 CET
CureVac, Q&M Dental, Moderna - What you didn't know - really exciting!
The World Health Organization (WHO) recorded more than 235 Covid-19 vaccine projects worldwide since January 2020, but few projects make it across the finish line. Timing is a critical factor, and early entrants will divide the huge market among themselves. These include BioNTech/Pfizer, Moderna and AstraZeneca. Still in the "test phase" is Tübingen-based CureVac, which recently entered into a sales cooperation with Bayer. Information published yesterday is positive and suggests approval of the preparation by the beginning of the second quarter of 2021 at the latest. Away from vaccine manufacturers, other Corona profiteers exist with which investors can earn handsomely. Q&M Dental from Singapore is little known. Its subsidiary is one of nine government-approved Corona testing facilities. Also, Q&M supplies Asian neighboring countries with millions of its Corona testing. We inform you about the news and potentials of known and unknown players.
Read
Commented by Mario Hose on June 18th, 2020 | 08:40 CEST
BioNTech, Evotec, EXMceuticals - which stocks have the potential to double?
Experienced investors assume that the DAX, Germany's leading index, will still reach new highs in 2020. One of the best-known supporters of this scenario is the asset manager Dr. Jens Ehrhardt. Rising markets are supported by the measures taken by central banks and politicians - it is de facto the consequence of the increase in the money supply. This expected development will be of particular interest to those investors who have so far been on the sidelines and have to position themselves or reallocate.
Read
Commented by Mario Hose on June 16th, 2020 | 06:30 CEST
Gilead, Teva, XPhyto - Global marketing potential
The best business models solve problems and are scalable. In this context, the healthcare sector is particularly interesting. The world's population has recently reached 7.8 billion people and for this reason solutions can meet a large potential market with users. Cross-border solutions are needed not only for pandemics, but also for diseases that are not mentioned in the mass media but are nevertheless of great importance. A successful market launch is of equal interest to those affected and investors.
Read
Commented by Mario Hose on June 2nd, 2020 | 05:58 CEST
Memphasys, Moderna, Paion - Investments in solutions with potential
Biotech companies around the world employ scientists and physicians to study the causes of diseases. The research and development of medical products and solutions usually involves a large number of tests and takes a correspondingly long time. The longer and more extensive this process is, the more capital these companies require from investors. In the race to bring to market preparations or products that improve people's well-being or fulfill desires, the providers of solutions usually have great sales potential and investors may be bought out through a takeover.
Read
Commented by Mario Hose on May 26th, 2020 | 07:43 CEST
BioNTech, Evotec, XPhyto - will the next rally start?
Germany's leading index DAX closed the previous day at 11,391 points, its highest level since March 2020. At the beginning of the week the index of the 30 largest German companies gained 317 points compared to Friday, representing a gain of 2.87%. In the USA Wall Street remained closed on Monday due to the Memorial Day. As is well known, the stock market is where the future is traded and for this reason investors are already investing in the prospects of companies in the period following the Corona Pandemic. A rally has begun.
Read